Drug intelligence / Profile preview

cyprodime

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intraperitoneal
01

Overview

Cyprodime is a **synthetic morphinan derivative** that functions as a highly selective **μ-opioid receptor antagonist** (μ = mu opioid receptor) with minimal effects on δ- and κ-opioid receptors. Its structure belongs to the morphinan class, and it is primarily used in pharmacological research to selectively block μ-opioid receptor-mediated activity, allowing for dissecting the specific roles of the different opioid receptor subtypes within experimental settings. Unlike broad-spectrum antagonists like naloxone, cyprodime enables researchers to inactivate μ-opioid signaling specifically, making it valuable in studying opioid pharmacology and pain modulation pathways. There are no significant indications of clinical use, and it is mainly a laboratory research chemical[1][5][7][9].

Other names
cyprodime hydrochloride17-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-oneMorphinan-6-one, 17-(cyclopropylmethyl)-4,14-dimethoxy-
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on cyprodime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyprodime.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call